The aim was to analyze the clinical-laboratorial characteristics of CF at diagnosis in RJ where incidence is estimated as 1:6902. It is a descriptive and sectional study of patients followed from Jan/08 to Sept/09. The diagnosis was made through the manifestation of the disease plus the sweat test. PI was defined by enzyme replacement; malnutrition weight/age, weight/stature/age, gender in 2 yo, and BMI for >2 yo; morbidity; manifestations and hospitalization. In 105 patients, 55% were female, 58% white and 97% RJ residents. We verified a delay of 11 months between median ages at diagnosis and the onset of symptoms: 14 mo and 1.7 mo. CF was manifested by meconial ileum (9.6%); edema and anemia (9.6%); dehydration (29.8%); poor absorption (85%); PI (89.5%); malnutrition in patients aged 2 (54.1%) and >2 (44.2%); coughing (87.6%), dyspnea (75.2%), thoracic deformity (30.5%), digital hippocratism (28.6%), P. aeruginosa (45.6%), S. aureus (34.4%), B. cepacia complex (5.6%). Patients who needed hospital treatment (46.7%), 66% with previous hospitalizations, 61% <1 yo. Identified mutations in 2 alleles in 38.6%: DF508/DF508 (15/70), DF508/other (7), other/other (1); and in 1 allele 40%: DF508/Unknown(U) (18), other/U (10), and U/U (15/70). We highlight the following possible risk factors associated with morbidity: difficulty, delay and confusing it with comorbidities associated with prevalent diseases − malnutrition, diarrhea, dehydration, pneumonia, in addition to severe mutations. Early diagnosis and adequate interventions are necessary to reduce morbimortality which contrasts with the challenge posed on the genotypic determination of the studied population for therapeutical ends. Free and open software were adopted for programming, and the security of the system was planned in several layers using interceptions provided by the Struts2 framework. The main contents of the registry were Demographics, Diagnosis data and Clinical data. This last item would be inserted annually, including number of consultations, nutritional and functional data, current treatments, microbiology data and Schwachman-Kulczycki score. Identification of patients is protected. After initial testing of the platform, all known Centers and health professionals involved in CF care were invited to join the Registry. A formal contract was celebrated among the GBEFC and each Center to guarantee the confidentiality of the data. The start of data insertion took place in March 2010, but was very modest until the occurrence of the Brazilian CF Congress in September 2010. Approximately 1,400 patients were included until January 2011 (near one-third of all Brazilian CF patients).
Conclusions:
The new Brazilian CF Registry is fully operational but strategies to improve adhesion are needed.
